Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 39 of 184 for:    Foradil Combi OR symbicort OR (Budesonide AND formeterol)

Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00573222
Recruitment Status : Completed
First Posted : December 14, 2007
Last Update Posted : December 1, 2010
Sponsor:
Information provided by:
AstraZeneca

Tracking Information
First Submitted Date December 13, 2007
First Posted Date December 14, 2007
Last Update Posted Date December 1, 2010
Study Start Date November 2007
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: December 13, 2007)
To evaluate & describe asthma control in adult patients w/moderate to severe asthma treated w/Symbicort SMART following the frequency, type & severity of symptoms through the Asthma Control Questionnaire.
Original Primary Outcome Measures Same as current
Change History Complete list of historical versions of study NCT00573222 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: December 13, 2007)
to evaluate the safety of Symbicort SMART treatment through the number and type of reported adverse events 2. assessment of patient's satisfaction with the treatment 3.assessment of physician's satisfaction with the treatment
Original Secondary Outcome Measures Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
Official Title Non-interventional Surveillance of Effectiveness of Symbicort® Maintenance And Reliever Therapy (Symbicort® SMART) in the Treatment of Moderate and Severe Asthma
Brief Summary This is a 3-month non-interventional, observational study on patients with moderate and severe asthma.
Detailed Description Not Provided
Study Type Observational
Study Design Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population pulmonology clinics
Condition Asthma
Intervention Drug: Symbicort
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: July 16, 2009)
330
Original Estimated Enrollment
 (submitted: December 13, 2007)
400
Actual Study Completion Date May 2008
Actual Primary Completion Date May 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients with moderate and severe asthma on Symbicort SMART treatment

Exclusion Criteria:

  • Under 18 years old
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Croatia
Removed Location Countries  
 
Administrative Information
NCT Number NCT00573222
Other Study ID Numbers NIS-RHR-SYM-2007/1
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Not Provided
Study Sponsor AstraZeneca
Collaborators Not Provided
Investigators
Study Director: Anan Marija Gjurovic AstraZeneca
PRS Account AstraZeneca
Verification Date November 2010